• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

    7/15/21 4:30:00 PM ET
    $CLPT
    $ACLS
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Technology
    Get the next $CLPT alert in real time by email

    SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee.

    Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position since May 2005, having initially joined Axcelis in 2001 as a Senior Vice President and General Counsel. As a member of Axcelis' executive team for more than 20 years, Ms. Fallon has been involved with business development, financial and tax management, investor relations, diversity and inclusion initiatives, corporate social responsibility policies and other ESG matters, M&A, risk management, and all aspects of international corporate compliance. She holds a J.D., cum laude, from the School of Law at Boston University and a B.A. with departmental and general honors, Phi Beta Kappa, from Vassar College.

    "We are thrilled to have Lynnette join the ClearPoint Board and to begin her contributions immediately," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Lynnette's role will benefit our growing company in many different and crucial facets, including human resources, M&A, legal, and investor relations. We are all looking forward to getting started."

    "I am honored to join the ClearPoint Neuro Board," stated Lynnette Fallon. "The Company is at an exciting juncture, and I hope to use my skills and experience to contribute to its continuing success."

    About ClearPoint Neuro

    ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company's current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with over 30 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 4,500 cases have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners. For more information, please visit www.clearpointneuro.com.

    Forward-Looking Statements

    Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company's ClearPoint Neuro Navigation System products; and the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2021, both of which have been filed with the Securities and Exchange Commission.



    Contact:
    
    Jacqueline Keller, Vice President, Marketing
    1 (888) 287-9109
    [email protected]
    
    Caroline Corner, Investor Relations
    [email protected]

    Primary Logo

    Get the next $CLPT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLPT
    $ACLS

    CompanyDatePrice TargetRatingAnalyst
    Axcelis Technologies Inc.
    $ACLS
    4/21/2025$50.00Buy → Neutral
    B. Riley Securities
    Axcelis Technologies Inc.
    $ACLS
    2/12/2025Outperform → Mkt Perform
    William Blair
    Axcelis Technologies Inc.
    $ACLS
    11/8/2024Buy → Hold
    The Benchmark Company
    ClearPoint Neuro Inc.
    $CLPT
    7/25/2024$10.00Buy
    B. Riley Securities
    Axcelis Technologies Inc.
    $ACLS
    5/3/2024$130.00Hold → Buy
    Craig Hallum
    Axcelis Technologies Inc.
    $ACLS
    12/15/2023Buy → Neutral
    BofA Securities
    ClearPoint Neuro Inc.
    $CLPT
    10/24/2023$8.00Buy
    Stifel
    Axcelis Technologies Inc.
    $ACLS
    9/15/2023$225.00Buy
    BofA Securities
    More analyst ratings

    $CLPT
    $ACLS
    SEC Filings

    See more
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      6/17/25 4:15:28 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by ClearPoint Neuro Inc.

      144 - ClearPoint Neuro, Inc. (0001285550) (Subject)

      6/3/25 4:13:31 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Axcelis Technologies Inc.

      S-8 - AXCELIS TECHNOLOGIES INC (0001113232) (Filer)

      5/29/25 5:16:43 PM ET
      $ACLS
      Industrial Machinery/Components
      Technology

    $CLPT
    $ACLS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLPT
    $ACLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Low Russell bought $49,452 worth of shares (440 units at $112.39), increasing direct ownership by 0.77% to 57,754 units (SEC Form 4)

      4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

      3/11/24 4:15:28 PM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Coogan James Gordon bought $11,223 worth of shares (100 units at $112.23), increasing direct ownership by 2% to 5,991 units (SEC Form 4)

      4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

      2/29/24 4:15:26 PM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Lawson Douglas A. bought $55,520 worth of shares (500 units at $111.04), increasing direct ownership by 3% to 19,648 units (SEC Form 4)

      4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

      2/26/24 8:15:07 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology

    $CLPT
    $ACLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Axcelis Tech downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Axcelis Tech from Buy to Neutral and set a new price target of $50.00

      4/21/25 8:31:51 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Axcelis Tech downgraded by William Blair

      William Blair downgraded Axcelis Tech from Outperform to Mkt Perform

      2/12/25 6:59:21 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Axcelis Tech downgraded by The Benchmark Company

      The Benchmark Company downgraded Axcelis Tech from Buy to Hold

      11/8/24 7:32:05 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology

    $CLPT
    $ACLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer D'Alessandro Danilo was granted 376 shares, increasing direct ownership by 0.57% to 66,368 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:13:49 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Business Officer Stigall L. Jeremy was granted 1,608 shares, increasing direct ownership by 2% to 72,355 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:11:30 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Sabra Mazin was granted 361 shares, increasing direct ownership by 0.71% to 51,564 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:08:46 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    $ACLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axcelis Announces Participation in Upcoming Investor Conferences

      BEVERLY, Mass., May 7, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the following upcoming investor conferences: The 53rd Annual J.P. Morgan Global Technology, Media and Communications Conference on May 14th at the Westin Boston Seaport District.The 25th Annual B. Riley Investor Conference on Wednesday, May 21st at the Ritz-Carlton, Marina del Rey, CA.  The 53rd Annual TD Cowen Technology, Media & Telecom Conference on Wedn

      5/7/25 8:01:00 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Axcelis Announces Financial Results for First Quarter 2025

      Q1 Highlights: Revenue of $192.6 millionGAAP Gross Margin of 46.1%, and Non-GAAP Gross Margin of 46.4%GAAP Operating Margin of 15.1% and Non-GAAP Operating Margin of 18.3%GAAP Diluted earnings per share of $0.88, and Non-GAAP Diluted earnings per share of $1.04BEVERLY, Mass., May 6, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS) today announced financial results for the first quarter ended March 31, 2025. President and CEO Russell Low commented, "We executed well in the first quarter, delivering strong profitability despite a moderation in customer investments a

      5/6/25 7:00:00 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Axcelis Announces Participation in Advanced Semiconductor Manufacturing Conference (ASMC)

      BEVERLY, Mass., April 24, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that it will be a sponsor for the Advanced Semiconductor Manufacturing Conference (ASMC) on May 5-8, 2025, at the Hilton Albany, in Albany, New York. This event brings together manufacturers, equipment and materials suppliers, and academia to solve manufacturing challenges with innovative strategies and methodologies. Axcelis will present in Session 5: Contamination Free Manufacturing:

      4/24/25 8:00:00 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology

    $CLPT
    $ACLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Axcelis Technologies Appoints David Ryzhik Senior Vice President of Investor Relations and Corporate Strategy

      The Company Announces Planned Retirement of Doug Lawson, Executive Vice President of Corporate Marketing and Strategy BEVERLY, Mass., June 27, 2024 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today named David Ryzhik as Senior Vice President of Investor Relations and Corporate Strategy, assuming responsibility for the role in July 2024. The Company also announced the retirement of Doug Lawson, Executive Vice President of Corporate Marketing and Strategy. Mr. Lawson plans to retire in July 2024 and will remain as a Senior Advisor through July 2025.

      6/27/24 4:01:00 PM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Axcelis Announces Shipment of 'Purion EXE SiC Power Series' Implanter and Successful 'Purion H200 SiC Power Series' Eval Closure at Leading Power Device Manufacturers in Japan

      BEVERLY, Mass., April 2, 2024 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today a shipment of the Company's Purion EXE™ SiC high energy implanter as well as a successful Purion H200™ SiC medium energy implanter evaluation closure at leading power device chipmakers located in Japan. The systems will be used for 150mm and 200mm production of silicon carbide power devices supporting automotive, industrial, energy, and other power intensive applications. Greg Redinbo,

      4/2/24 8:00:00 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

      SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

      9/20/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    $ACLS
    Financials

    Live finance-specific insights

    See more
    • Axcelis Announces Financial Results for First Quarter 2025

      Q1 Highlights: Revenue of $192.6 millionGAAP Gross Margin of 46.1%, and Non-GAAP Gross Margin of 46.4%GAAP Operating Margin of 15.1% and Non-GAAP Operating Margin of 18.3%GAAP Diluted earnings per share of $0.88, and Non-GAAP Diluted earnings per share of $1.04BEVERLY, Mass., May 6, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS) today announced financial results for the first quarter ended March 31, 2025. President and CEO Russell Low commented, "We executed well in the first quarter, delivering strong profitability despite a moderation in customer investments a

      5/6/25 7:00:00 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Axcelis Announces Timing and Availability of First Quarter 2025 Results and Conference Call

      BEVERLY, Mass., April 17, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry will release financial results for the first quarter 2025 before the opening of the market on Tuesday, May 6, 2025. The Company will host a call the same day to discuss the results at 8:30 a.m. ET. The call will be available via webcast that can be accessed through the Investors page of Axcelis' website at www.axcelis.com, or by registering as a participant here: https://register-conf.media-server.com/

      4/17/25 8:00:00 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology
    • Axcelis Announces Financial Results for Fourth Quarter and Full Year 2024

      Q4 Highlights: Revenue of $252.4 millionOperating Margin of 21.6%Diluted earnings per share of $1.54BEVERLY, Mass., Feb. 10, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS) today announced financial results for the fourth quarter and full year ended December 31, 2024. For the full year 2024, the Company reported revenue of $1.02 billion, compared with $1.13 billion for the full year 2023. Systems revenue for the year was $782.6 million, compared to $883.6 million in 2023. Operating profit was $210.8 million in 2024, compared to $265.8 million in 2023. Net income

      2/10/25 4:01:00 PM ET
      $ACLS
      Industrial Machinery/Components
      Technology

    $CLPT
    $ACLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/12/24 2:35:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/8/24 4:33:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Axcelis Technologies Inc.

      SC 13G/A - AXCELIS TECHNOLOGIES INC (0001113232) (Subject)

      11/8/24 2:17:22 PM ET
      $ACLS
      Industrial Machinery/Components
      Technology